![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
在t(11;14) 阳性复发性/耐药性多发性髓瘤中使用venetoclax:系统性审查
Wardah Javed Khan1, Mubeen Ali1, Sana Hashim2
1Demonstrator (Teaching Faculty) Pharmacology and Therapeutics, Northwest School of Medicine, Peshawar, Pakistan.
概括
威尼托克拉克斯在治疗复发性/耐药性多发性骨髓瘤 (RRMM) 中表现有前途,具有t(11;14) 转位. 这种BCL-2抑制剂具有良好的安全性,并有可能改善患者的治疗结果.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 多发性骨髓瘤 (MM) 是一种无法治愈的血细胞恶性瘤.
- 在MM中转位 (11;14) 与Bcl-2过度表达和治疗耐药性有关.
- 新型BCL-2抑制剂Venetoclax是一个潜在的治疗选择.
研究的目的:
- 系统地审查venetoclax在治疗复发性/耐药性多发性骨髓瘤 (RRMM) 的疗效.
- 评估venetoclax作为单一疗法和组合疗法.
- 评估venetoclax在该患者群体中的安全性和不良反应概况.
主要方法:
- 在遵守PRISMA指南的基础上进行系统审查.
- 在PubMed和Scopus数据库进行文献搜索.
- 包括10项涉及311名患者的研究,其中t(11;14) 阳性RRMM.
主要成果:
- 对venetoclax的总体应答率在33%至95.5%之间.
- 威尼托克拉克斯表现出有利的副作用,常见的副作用包括血液问题,恶心,吐和腹.
- 涉及维内托克拉克斯,德克萨米他,达拉图穆马布和卡菲尔佐米布的组合疗法显示出协同效应.
结论:
- 威尼托克拉克斯是t(11;14) 阳性RRMM的有前途的治疗药物.
- 与venetoclax的联合治疗方案可能会提高治疗效率和患者的治疗结果.
- 需要对venetoclax进行进一步的研究,以优化其在RRMM患者的临床实践中的使用.
相关概念视频
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
02:49Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K